Published in J R Soc Interface on June 05, 2013
Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00
Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse. J R Soc Interface (2014) 0.86
Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. Cancer Res (2014) 0.80
The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient-Specific Treatment Trajectories. Cancer Res (2016) 0.77
Robustness of differentiation cascades with symmetric stem cell division. J R Soc Interface (2014) 0.77
Feedback mechanisms control coexistence in a stem cell model of acute myeloid leukaemia. J Theor Biol (2016) 0.76
Emergence of heterogeneity in acute leukemias. Biol Direct (2016) 0.75
Hierarchical tissue organization as a general mechanism to limit the accumulation of somatic mutations. Nat Commun (2017) 0.75
The role of backward cell migration in two-hit mutants' production in the stem cell niche. PLoS One (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The serial cultivation of human diploid cell strains. Exp Cell Res (1961) 25.11
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Cancer genes and the pathways they control. Nat Med (2004) 24.22
The cancer genome. Nature (2009) 23.13
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Defining the epithelial stem cell niche in skin. Science (2003) 14.93
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Social controls on cell survival and cell death. Nature (1992) 9.81
G1 events and regulation of cell proliferation. Science (1989) 9.73
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Stochastic simulation of chemical kinetics. Annu Rev Phys Chem (2007) 7.59
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med (1999) 4.27
The telomere syndromes. Nat Rev Genet (2012) 4.01
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science (2008) 3.38
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med (2006) 3.13
Skin stem cells: rising to the surface. J Cell Biol (2008) 2.66
Cancer: drivers and passengers. Nature (2007) 2.11
Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood (2010) 1.81
Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A (1999) 1.75
Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle (2007) 1.68
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood (2009) 1.61
Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev (2009) 1.57
The stem cells of small intestinal crypts: where are they? Cell Prolif (2009) 1.55
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica (2009) 1.43
Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest (1985) 1.41
Perspectives on the properties of stem cells. Nat Med (2005) 1.25
Compartmental architecture and dynamics of hematopoiesis. PLoS One (2007) 1.19
Stochastic elimination of cancer cells. Proc Biol Sci (2003) 1.16
Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers. Proc Natl Acad Sci U S A (2011) 1.14
Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene (2005) 1.10
The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. Phys Biol (2011) 1.09
Allometric scaling of the active hematopoietic stem cell pool across mammals. PLoS One (2006) 1.05
Cellular aging leads to functional heterogeneity of hematopoietic stem cells: a modeling perspective. Aging Cell (2011) 1.03
Dynamics of mutant cells in hierarchical organized tissues. PLoS Comput Biol (2011) 0.99
Initiation of colorectal cancer: where do the two hits hit? Cell Cycle (2004) 0.99
On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. J R Soc Interface (2012) 0.97
Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2013) 0.92
Ontogenic growth of the haemopoietic stem cell pool in humans. Proc Biol Sci (2007) 0.87
Evolving homeostatic tissue using genetic algorithms. Prog Biophys Mol Biol (2011) 0.83
A comprehensive mathematical model of stem cell proliferation which reproduces most of the published experimental results. Cell Tissue Kinet (1980) 0.82
Explaining the in vitro and in vivo differences in leukemia therapy. Cell Cycle (2011) 0.80
Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data. PLoS One (2011) 0.79
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Via freedom to coercion: the emergence of costly punishment. Science (2007) 5.12
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Social learning promotes institutions for governing the commons. Nature (2010) 3.00
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Coevolution of strategy and structure in complex networks with dynamical linking. Phys Rev Lett (2006) 2.73
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Evolutionary games in the multiverse. Proc Natl Acad Sci U S A (2010) 2.06
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Active linking in evolutionary games. J Theor Biol (2006) 1.74
Evolution of cooperation on stochastic dynamical networks. PLoS One (2010) 1.73
Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle (2007) 1.68
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood (2011) 1.46
Cyclic neutropenia in mammals. Am J Hematol (2008) 1.43
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica (2009) 1.43
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol (2008) 1.39
(A)symmetric stem cell replication and cancer. PLoS Comput Biol (2007) 1.36
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood (2012) 1.32
Emergence of responsible sanctions without second order free riders, antisocial punishment or spite. Sci Rep (2012) 1.29
Mutation-selection equilibrium in games with multiple strategies. J Theor Biol (2009) 1.26
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer (2011) 1.20
Does intra-individual major histocompatibility complex diversity keep a golden mean? Philos Trans R Soc Lond B Biol Sci (2009) 1.20
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol (2008) 1.19
Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol (2008) 1.19
Compartmental architecture and dynamics of hematopoiesis. PLoS One (2007) 1.19
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood (2011) 1.19
Adaptive dynamics of extortion and compliance. PLoS One (2013) 1.18
Speciation accelerated and stabilized by pleiotropic major histocompatibility complex immunogenes. Ecol Lett (2009) 1.15
The different limits of weak selection and the evolutionary dynamics of finite populations. J Theor Biol (2007) 1.15
Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol (2010) 1.14
Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol (2009) 1.13
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc (2008) 1.13
Consistent strategy updating in spatial and non-spatial behavioral experiments does not promote cooperation in social networks. PLoS One (2012) 1.12
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol (2011) 1.11
Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol (2008) 1.09
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
How mutation affects evolutionary games on graphs. J Theor Biol (2011) 1.09
Repeated games and direct reciprocity under active linking. J Theor Biol (2007) 1.08
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
How small are small mutation rates? J Math Biol (2011) 1.08
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol (2010) 1.08
Cyclic dominance and biodiversity in well-mixed populations. Phys Rev Lett (2008) 1.08
Universality of weak selection. Phys Rev E Stat Nonlin Soft Matter Phys (2010) 1.08
Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica (2013) 1.07
Evolutionary dynamics of strategic behavior in a collective-risk dilemma. PLoS Comput Biol (2012) 1.07
Strategy abundance in 2x2 games for arbitrary mutation rates. J Theor Biol (2008) 1.06
Static network analysis of a pork supply chain in Northern Germany-Characterisation of the potential spread of infectious diseases via animal movements. Prev Vet Med (2013) 1.05
The pace of evolution across fitness valleys. J Theor Biol (2009) 1.04
Shame and honour drive cooperation. Biol Lett (2011) 1.03
Outcomes of patients with POEMS syndrome treated initially with radiation. Blood (2013) 1.02
Using underdominance to bi-stably transform local populations. J Theor Biol (2010) 1.02
Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol (2012) 1.01
Non-Gaussian fluctuations arising from finite populations: Exact results for the evolutionary Moran process. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 1.00
Democratic decisions establish stable authorities that overcome the paradox of second-order punishment. Proc Natl Acad Sci U S A (2013) 1.00
Dynamics of mutant cells in hierarchical organized tissues. PLoS Comput Biol (2011) 0.99
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol (2013) 0.99
Public goods with punishment and abstaining in finite and infinite populations. Biol Theory (2008) 0.98
The effect of population structure on the rate of evolution. Proc Biol Sci (2013) 0.98
Leaving the loners alone: evolution of cooperation in the presence of antisocial punishment. J Theor Biol (2012) 0.97
On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. J R Soc Interface (2012) 0.97
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer (2012) 0.97
On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells (2007) 0.96
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant (2012) 0.95
Stochastic slowdown in evolutionary processes. Phys Rev E Stat Nonlin Soft Matter Phys (2010) 0.94
Multiple mutant clones in blood rarely coexist. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 0.94
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol (2011) 0.94
Emergence of stable polymorphisms driven by evolutionary games between mutants. Nat Commun (2012) 0.94
Bacterial colonization of Hydra hatchlings follows a robust temporal pattern. ISME J (2013) 0.93
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol (2009) 0.92
The mechanics of stochastic slowdown in evolutionary games. J Theor Biol (2012) 0.91
Extrapolating weak selection in evolutionary games. PLoS Comput Biol (2013) 0.90
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood (2011) 0.90
Stability properties of underdominance in finite subdivided populations. PLoS Comput Biol (2011) 0.90
Lotka-Volterra dynamics kills the Red Queen: population size fluctuations and associated stochasticity dramatically change host-parasite coevolution. BMC Evol Biol (2013) 0.90
Deterministic evolutionary game dynamics in finite populations. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 0.90
Fixation probabilities of random mutants under frequency dependent selection. J Theor Biol (2009) 0.89
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer (2005) 0.89
Cancer biology: infectious tumour cells. Nature (2006) 0.87
Acquired hematopoietic stem-cell disorders and mammalian size. Blood (2007) 0.87